US equities |
META $630.56 ▲+0.00% MU $903.70 ▲+0.00% NVDA $216.00 ▲+0.00% TSLA $391.62 ▲+0.00% INTC $90.47 ▲+0.00% SPCX $146.90 ▲+0.00% AMD $531.28 ▲+0.00% SNDK $1,255.58 ▲+0.00%
FinancialContent

Invivyd, Inc. - Common Stock (NQ:IVVD)

0.5892 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Invivyd, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor
From Invivyd
Via GlobeNewswire
News headline image
Earnings Outlook For Invivyd ↗
 
Via Benzinga
News headline image
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to
From Invivyd
Via GlobeNewswire
News headline image
Earnings Scheduled For November 14, 2024 ↗
 
Via Benzinga
News headline image
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024
From Invivyd
Via GlobeNewswire
News headline image
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate in Upcoming Investor Conferences
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial
From Invivyd
Via GlobeNewswire
News headline image
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
IVVD Stock Earnings: Invivyd Misses EPS, Misses Revenue for Q2 2024 ↗
IVVD stock results show that Invivyd missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate at the Jefferies Global Healthcare Conference
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)
From Invivyd
Via GlobeNewswire
News headline image
Invivyd Elects Two New Independent Members to its Board of Directors
From Invivyd
Via GlobeNewswire
News headline image
Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Invivyd
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >